Apotex, one of Canada's largest pharmaceutical companies, is planning to sell approximately $1 billion in shares through an initial public offering (IPO), according to sources familiar with the matter. The move would mark a significant milestone for the Toronto-based generic drug manufacturer, which has been privately held since its founding in 1974.
IPO Details and Market Impact
The company is reportedly working with investment banks to underwrite the offering, which could be launched later this year. Apotex has not yet confirmed the timeline or valuation, but industry analysts estimate the company could be valued at several billion dollars. The IPO would allow the Sherman family, which controls Apotex, to monetize part of their stake while raising capital for expansion.
If successful, the IPO would be one of the largest in Canadian history for a pharmaceutical company. It comes amid a wave of healthcare IPOs globally, as investors seek exposure to the resilient drug sector. Apotex's generic portfolio includes hundreds of medications, making it a key player in affordable healthcare.
Company Background and Growth
Apotex was founded by Barry Sherman, who built it into a global generic drug powerhouse. After his tragic death in 2017, the company has been led by his family and professional management. The firm has expanded through acquisitions and research, with operations in over 100 countries. Proceeds from the IPO could be used to fund new drug development, expand manufacturing, or pay down debt.
The offering is expected to attract strong interest from institutional investors, given Apotex's stable cash flows and market position. However, the company faces challenges from pricing pressures and competition. The IPO will also test investor appetite for Canadian pharmaceutical stocks.
Industry Context
The generic drug market is highly competitive, with margins under pressure from consolidation among buyers. Apotex has responded by focusing on complex generics and biosimilars, which offer higher profitability. The IPO could provide the financial firepower to accelerate these efforts.
Canadian regulators will review the offering for compliance with securities laws. The company will need to disclose detailed financials and risk factors in its prospectus. If all goes as planned, Apotex shares could begin trading on the Toronto Stock Exchange by late 2026.
